Empagliflozin May Reduce Cardiovascular Mortality in T2D With Left Ventricular Hypertrophy
For patients with type 2 diabetes and left ventricular hypertrophy, empagliflozin reduced the risk for cardiovascular death vs placebo.
Type 2 Diabetes
Risk for Diabetic Retinopathy Associated With Apnea-Hypopnea Index During REM Sleep
Apnea-hypopnea index during REM sleep is independently associated with diabetic retinopathy in patients with type 2 diabetes.
Poor Glycemic Control Increases Fracture Risk in T1D
Poor glycemic control in patients with newly diagnosed type 1 diabetes, but not type 2 diabetes, was associated with an increased risk for low-trauma fracture.
Treating Albuminuria Reduces CV Events, Death in Type 2 Diabetes
Suppressing albuminuria should be an important target of therapy, according to investigators.
Case: Metformin Abuse for Weight Loss Purposes in a Patient Without Diabetes
The patient, who had a history of anorexia nervosa-binge purge type, presented to the emergency department with severe abdominal pain, confusion, disorientation, and was experiencing visual hallucinations.
Hospitalizations for Young-Onset T2D and the Impact of Mental Illness
Compared with patients who have onset type 2 diabetes at a usual age, adults with young-onset type 2 diabetes are hospitalized significantly more often in their lifetimes.
Small Increase in HbA1c After Switching From Analog to Human Insulin in T2D
Switching from analogue to human insulin is associated with a small increase in hemoglobin A1c (HbA1c) levels.
Does DPP-4 Inhibitor Use Increase the Risk of Developing IBD?
To investigate the association between this diabetes drug class and IBD risk, the study authors searched various databases for controlled clinical trials and observational studies involving DPP-4 inhibitors where IBD events were reported.
Relationship Between Cardiorespiratory Fitness and Type 2 Diabetes Risk
An inverse dose-dependent association exists between cardiorespiratory fitness and type 2 diabetes risk.
Oral Hepatoselective Glucokinase Activator Promising in T2D
Use of the oral hepatoselective glucokinase activator (GKA) TTP399 for type 2 diabetes does not cause hypoglycemia and has no detrimental effect on plasma lipids or liver enzymes.
